(Q37211086)

19 August 2017

Successful treatment of membranous glomerulonephritis with rituximab in calcineurin inhibitor-dependent patients (English)

1 reference

membranous glomerulonephritis

19 August 2017

1 reference

1 reference

1 reference

Alfons Segarra

1

1 reference

19 August 2017

Manuel Praga

2

1 reference

19 August 2017

Natalia Ramos

3

1 reference

19 August 2017

Natalia Polanco

4

1 reference

19 August 2017

Isabel Cargol

5

1 reference

19 August 2017

Elena Gutierrez-Solis

6

1 reference

19 August 2017

M Rosa Gomez

7

1 reference

19 August 2017

Bruno Montoro

8

1 reference

19 August 2017

Joaquim Camps

9

1 reference

19 August 2017

language of work or name

1 reference

28 May 2009

1 reference

Clinical Journal of the American Society of Nephrology

19 August 2017

1 reference

19 August 2017

4

1 reference

19 August 2017

6

1 reference

19 August 2017

1083-1088

1 reference

A review of the current use of rituximab in autoimmune diseases

19 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2689890

Anti-CD20 therapy and autoimmune disease: therapeutic opportunities and evolving insights

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2689890

Drug insight: rituximab in renal disease and transplantation

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2689890

New insights into the pathogenesis of membranous glomerulonephritis

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2689890

Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2689890

Diagnosis and natural course of membranous nephropathy

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2689890

Cyclosporine in patients with steroid-resistant membranous nephropathy: a randomized trial

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2689890

Analysis of prognostic predictors in idiopathic membranous nephropathy

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2689890

IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2689890

Immunocytochemical localization of the Heymann nephritis antigen (GP330) in glomerular epithelial cells of normal Lewis rats

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2689890

Rituximab treatment of idiopathic membranous nephropathy

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2689890

Rituximab in idiopathic membranous nephropathy: a one-year prospective study

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2689890

Rituximab: an insider's historical perspective.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2689890

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2689890

Validation of a predictive model of idiopathic membranous nephropathy: its clinical and research implications.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2689890

Titrating Rituximab to Circulating B Cells to Optimize Lymphocytolytic Therapy in Idiopathic Membranous Nephropathy

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2689890

Rituximab for Idiopathic Membranous Nephropathy: Who Can Benefit?

4 December 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2689890

Inhibition of the CD40-CD40ligand pathway prevents murine membranous glomerulonephritis

4 December 2018

1 reference

12 December 2020

A controlled trial of cyclosporine in patients with progressive membranous nephropathy. Canadian Glomerulonephritis Study Group

1 reference

12 December 2020

CD20-positive infiltrates in human membranous glomerulonephritis

1 reference

12 December 2020

Induction and long-term treatment with cyclosporine in membranous nephropathy with the nephrotic syndrome

1 reference

12 December 2020

Tacrolimus monotherapy in membranous nephropathy: a randomized controlled trial

1 reference

12 December 2020

A 10-year follow-up of a randomized study with methylprednisolone and chlorambucil in membranous nephropathy

1 reference

12 December 2020

Rituximab for idiopathic membranous nephropathy

1 reference

12 December 2020

Predicting chronic renal insufficiency in idiopathic membranous glomerulonephritis

1 reference

12 December 2020

Identifiers

DOI

10.2215/CJN.06041108

1 reference

19 August 2017

1 reference

19 August 2017

1 reference